Nothing Special   »   [go: up one dir, main page]

EA201991065A1 - Вакцина против свиного парвовируса - Google Patents

Вакцина против свиного парвовируса

Info

Publication number
EA201991065A1
EA201991065A1 EA201991065A EA201991065A EA201991065A1 EA 201991065 A1 EA201991065 A1 EA 201991065A1 EA 201991065 A EA201991065 A EA 201991065A EA 201991065 A EA201991065 A EA 201991065A EA 201991065 A1 EA201991065 A1 EA 201991065A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
residue
subject
amino acid
relates
Prior art date
Application number
EA201991065A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991065A1 publication Critical patent/EA201991065A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение касается, в числе прочего, вирусного белка 2 (VP2) свиного парвовируса (PPV), имеющего в аминокислотной позиции 228 глутаминово-кислотный остаток или глутаматный остаток, и/или в аминокислотной позиции 414 сериновый остаток, и/или в аминокислотной позиции 419 глутаминовый остаток, и/или в аминокислотной позиции 436 треониновый остаток. Кроме того, настоящее изобретение касается иммуногенных композиций, включающих вирусный белок 2 (VP2) свиного парвовируса (PPV). Кроме того, настоящее изобретение касается способов иммунизации субъекта, включающих введение такому субъекту иммуногенной композиции согласно настоящему изобретению. Кроме того, настоящее изобретение касается способов лечения или предотвращения клинических признаков вызываемых инфекцией PPV у субъекта, который в этом нуждается, причем способ включает введение субъекту терапевтически эффективного количества иммуногенной композиции согласно настоящему изобретению.
EA201991065A 2016-11-03 2017-11-02 Вакцина против свиного парвовируса EA201991065A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16197091 2016-11-03
PCT/EP2017/078015 WO2018083154A1 (en) 2016-11-03 2017-11-02 Vaccine against porcine parvovirus

Publications (1)

Publication Number Publication Date
EA201991065A1 true EA201991065A1 (ru) 2019-11-29

Family

ID=57223617

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991065A EA201991065A1 (ru) 2016-11-03 2017-11-02 Вакцина против свиного парвовируса

Country Status (16)

Country Link
US (2) US10485866B2 (ru)
EP (1) EP3534945A1 (ru)
JP (2) JP6876127B2 (ru)
KR (2) KR20240090735A (ru)
CN (1) CN109803678B (ru)
AU (1) AU2017353378B2 (ru)
BR (1) BR112019009133A2 (ru)
CA (1) CA3042573A1 (ru)
CL (1) CL2019001049A1 (ru)
EA (1) EA201991065A1 (ru)
MX (1) MX2019005137A (ru)
MY (1) MY191490A (ru)
PH (1) PH12019500954A1 (ru)
TW (1) TWI781962B (ru)
UA (1) UA127859C2 (ru)
WO (1) WO2018083154A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
KR102664662B1 (ko) 2016-11-03 2024-05-14 베링거잉겔하임베트메디카게엠베하 돼지 파보바이러스 및 돼지 생식기 및 호흡기 증후군 바이러스에 대한 백신 및 이의 제조 방법
EA201991065A1 (ru) 2016-11-03 2019-11-29 Вакцина против свиного парвовируса
US11013796B2 (en) 2018-08-30 2021-05-25 Iowa State University Research Foundation, Inc. Porcine parainfluenza virus type 1 isolates and immunogenic compositions therefrom
KR102117811B1 (ko) * 2018-12-05 2020-06-02 대한민국(농림축산식품부 농림축산검역본부장) 재조합 돼지파보바이러스 항원 단백질 및 이의 용도
WO2020206452A1 (en) 2019-04-04 2020-10-08 Boehringer Ingelheim Animal Health USA Inc. Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
CN110845580A (zh) * 2019-11-05 2020-02-28 中国农业科学院兰州兽医研究所 一种猪细小病毒样颗粒的组装及其免疫原性鉴定方法
KR102550709B1 (ko) 2021-05-03 2023-07-06 대한민국 돼지 생식기 호흡기 증후군 바이러스 PRRS2/Kor/CBJE19/2010 바이러스주
KR102550701B1 (ko) 2021-05-03 2023-07-05 대한민국 돼지 생식기 호흡기 증후군 바이러스 PRRS2/Kor/GGYC45/2010 바이러스주
KR102550715B1 (ko) 2021-05-03 2023-07-05 대한민국 돼지 생식기 호흡기 증후군 바이러스 PRRS2/Kor/GBGJ22/2011 바이러스주
CN114480439A (zh) * 2022-02-23 2022-05-13 成都史纪生物制药有限公司 一种猪细小病毒vp2蛋白基因及其应用
CN117866053B (zh) * 2024-01-10 2024-07-02 武汉珈创生物技术股份有限公司 同时检测多种猪细小病毒的多克隆抗体及其制备和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
EP0117767A1 (en) 1983-01-07 1984-09-05 Mgi Pharma, Inc. Production of parvovirus subunit vaccines
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
AU7966987A (en) 1986-09-08 1988-04-07 Applied Biotechnology, Inc. Empty viral capsid vaccines
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
CA2357538A1 (en) 1989-03-21 1990-10-04 Wisconsin Alumni Research Foundation Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
ES2026827A6 (es) * 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
WO1995020660A2 (en) 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
DE69534289T2 (de) 1994-04-29 2006-04-27 Baxter Healthcare S.A. Rekombinante Pockenviren mit fremden Polynukleotiden in wichtigen Regionen
AU711702B2 (en) 1995-03-23 1999-10-21 Cambridge University Technical Services Limited Vectors for gene delivery
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
RU2269361C2 (ru) 2004-03-25 2006-02-10 Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ ВНИИЗЖ) Вакцина ассоциированная эмульсионная инактивированная против репродуктивно-респираторного синдрома и парвовирусной инфекции свиней
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
AU2011222910B2 (en) 2010-03-05 2014-09-18 Intervet International B.V. Recombinant attenuated parvovirus
TWI442935B (zh) 2010-12-22 2014-07-01 Sbc Virbac Ltd 豬第二型環狀病毒（Ｐｏｒｃｉｎｅ Ｃｉｒｃｏｖｉｒｕｓ Ｔｙｐｅ ２）、含彼之免疫組合物、檢測套組及其應用
CN102488895A (zh) 2011-12-30 2012-06-13 重庆大学 一种猪圆环病毒、猪细小病毒、猪繁殖与呼吸综合症病毒三联病毒样颗粒疫苗及其制备方法
CN102727881A (zh) 2012-07-04 2012-10-17 广东大华农动物保健品股份有限公司 高致病性猪繁殖与呼吸综合征jxa1-r株-猪细小病毒病二联活疫苗及其制备方法和应用
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
CN104288760A (zh) 2013-07-18 2015-01-21 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN105658660A (zh) * 2013-10-02 2016-06-08 勃林格殷格翰动物保健公司 Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
CN106039304B (zh) * 2016-05-28 2021-02-05 青岛易邦生物工程有限公司 一种猪细小病毒、猪流行性腹泻、大肠埃希氏菌三联疫苗
EA201991065A1 (ru) * 2016-11-03 2019-11-29 Вакцина против свиного парвовируса
KR102664662B1 (ko) 2016-11-03 2024-05-14 베링거잉겔하임베트메디카게엠베하 돼지 파보바이러스 및 돼지 생식기 및 호흡기 증후군 바이러스에 대한 백신 및 이의 제조 방법

Also Published As

Publication number Publication date
KR20240090735A (ko) 2024-06-21
WO2018083154A1 (en) 2018-05-11
BR112019009133A2 (pt) 2019-07-16
JP6876127B2 (ja) 2021-05-26
CA3042573A1 (en) 2018-05-11
KR102669319B1 (ko) 2024-05-28
AU2017353378B2 (en) 2024-03-14
TWI781962B (zh) 2022-11-01
MX2019005137A (es) 2019-06-20
CL2019001049A1 (es) 2019-08-16
CN109803678A (zh) 2019-05-24
CN109803678B (zh) 2023-08-22
UA127859C2 (uk) 2024-01-31
US10799578B2 (en) 2020-10-13
US20180133309A1 (en) 2018-05-17
US20200030438A1 (en) 2020-01-30
MY191490A (en) 2022-06-28
JP2021097679A (ja) 2021-07-01
JP2020500012A (ja) 2020-01-09
PH12019500954A1 (en) 2019-12-02
AU2017353378A1 (en) 2019-05-02
KR20190089899A (ko) 2019-07-31
EP3534945A1 (en) 2019-09-11
US10485866B2 (en) 2019-11-26
TW201829446A (zh) 2018-08-16

Similar Documents

Publication Publication Date Title
EA201991065A1 (ru) Вакцина против свиного парвовируса
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112018067964A2 (pt) agentes antivirais para hepatite b
EA201990071A1 (ru) Композиция пептидной вакцины
UY37998A (es) Agentes antivirales contra la hepatitis b
EA201992247A1 (ru) Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
EA202191967A1 (ru) Замещенные полициклические карбоновые кислоты, их аналоги и способы их применения
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
EA202191355A1 (ru) Стабилизированные f-белки rsv до слияния
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA201990717A1 (ru) Новая вакцина против гриппа свиней
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
CL2022002416A1 (es) Vacuna
PH12021550441A1 (en) Modified pedv spike protein
EA202192925A1 (ru) Твердые формы ингибитора glyt1
EA201690115A1 (ru) Комбинированные иммуногенные композиции
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком